Abelacimab

Names

[ CAS No. ]:
2098724-83-3

[ Name ]:
Abelacimab

Biological Activity

[Description]:

Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies[1][2].

[Related Catalog]:

Research Areas >> Cardiovascular Disease

Signaling Pathways >> Metabolic Enzyme/Protease >> Factor Xa

[In Vitro]

Abelacimab (MAA868) (0.0001-1 μM) 以浓度依赖的方式延长凝血时间并减少人血浆中的凝血酶数量[1]。

[In Vivo]

Abelacimab (MAA868) (s.c., 3-30 mg/kg, on day 1, 85, 114) 在食蟹猴中表现出强烈和持续的抗凝血作用，显着延长 aPTT，且具有较好的安全性，未观察到显着的毒性发现或出血迹象[1]。 Abelacimab (MAA868) (i.v., 0.6 mg/kg) 在氯化铁诱导的血栓形成 FXI-/- C57BL/6 小鼠模型中表现出良好的抗凝血活性，以防止颈动脉阻塞[1]。

[References]

[1]. Alexander W Koch, et al. MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood. 2019 Mar 28;133(13):1507-1516.

[2]. Elena Campello, et al. Clinical Pharmacology of Factor XI Inhibitors: New Therapeutic Approaches for Prevention of Venous and Arterial Thrombotic Disorders. J Clin Med. 2022 Oct 26;11(21):6314.

Chemical & Physical Properties

No Any Chemical & Physical Properties